IRadimed Q1 revenue rises 13% on new product launch

Overview

• MRI-compatible device maker's Q1 revenue rose 13% yr/yr to $22.0 mln

• Adjusted EPS for Q1 rose 17% yr/yr to $0.49

• Company says Q1 growth driven by launch of next-gen 3870 MRI IV pump

Outlook

• Company expects Q2 2026 revenue of $20 mln to $21 mln

• Company sees Q2 2026 GAAP diluted EPS of $0.40 to $0.44

• Company reaffirms 2026 revenue guidance of $91 mln to $96 mln

Result Drivers

• NEW PRODUCT LAUNCH - Co said Q1 growth was driven by commercial launch of next-generation 3870 MRI-compatible IV infusion pump, with strong early order activity and larger order sizes

• EXPENSE MANAGEMENT - Co said disciplined expense management contributed to improved operating income

Company press release: ID:nGNX4XfKVg

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for IRadimed Corp is $120.00, about 43.8% above its April 30 closing price of $83.44

• The stock recently traded at 39 times the next 12-month earnings vs. a P/E of 46 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.